Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RDY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | A Study to Evaluate Pharmacokinetics of DRL_AB in Healthy Male Participants NCT07744828 · Healthy Volunteers DRL_AB | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Not yet recruiting | 160 | Dec 29, 2026 | Registry ↗ |
| Jan 22, 2024 | Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabTher… NCT03976102 · Follicular Lymphoma DRL_RI (Proposed rituximab biosimilar), MabThera® | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 317 | Sep 28, 2022 | Registry ↗ |
| Nov 18, 2023 | A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products NCT04268771 · Rheumatoid Arthritis Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera® | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 140 | Jan 26, 2022 | Registry ↗ |
| Nov 13, 2023 | Comparative Pharmacokinetic Study of Three Abatacept Products in Male Normal Healthy Volunteers by… NCT06126042 · Rheumatoid Arthritis Test Product, Reference product | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Unknown | 330 | Apr 2024 | Registry ↗ |
| Apr 12, 2022 | A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Pl… NCT02173301 · Psoriasis XP23829 400 mg QD, XP 23829 800 mg QD | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 200 | May 2015 | Registry ↗ |
| Apr 1, 2022 | A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) NCT03421197 · Psoriasis PPC-06 400 mg QD, PPC-06 400 mg BID | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 426 | Mar 30, 2020 | Registry ↗ |
| Mar 21, 2022 | Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Pat… NCT04529499 · Covid19 AVIGAN, Placebo Comparator | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Terminated | 353 | Jan 22, 2021 | Registry ↗ |
| Jul 26, 2021 | Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion NCT02061813 · Head Lice Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 40 | Jan 2014 | Registry ↗ |
| Jul 9, 2021 | Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers NCT01518699 · Pediculosis Ha44, Ha44 Placebo | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 57 | May 2012 | Registry ↗ |
| Jun 2, 2021 | Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Sev… NCT04640233 · COVID-19 Prevention Gam-COVID-Vac, Placebo | RDY Dr. Reddy's Laboratories Limited | Phase 2/3 | Unknown | 1,600 | Aug 2021 | Registry ↗ |
| May 11, 2021 | Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice… NCT02097485 · Head Lice Infestation Abametapir Lotion 0.74% w/w, Vehicle Lotion | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 50 | Sep 2014 | Registry ↗ |
| Mar 1, 2021 | A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris NCT03599193 · Acne Vulgaris Tazarotene Lotion, 0.1%, Tazarotene Cream, 0.1% | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 58 | Apr 30, 2018 | Registry ↗ |
| Mar 1, 2021 | A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release… NCT03340961 · Rosacea DFD-29 Extended Release Capsules (40 mg), DFD-29 Extended R… | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 205 | Nov 7, 2018 | Registry ↗ |
| Mar 1, 2021 | A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks NCT03292640 · Acne Vulgaris DFD-03 (0.1% tazarotene) Lotion, DFD-03 (0% tazarotene) Lot… | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 547 | May 14, 2018 | Registry ↗ |
| Mar 1, 2021 | A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris NCT03290027 · Acne Vulgaris DFD-03, Placebo Comparator | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 550 | Apr 19, 2018 | Registry ↗ |
| Jan 22, 2021 | Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15 NCT03554772 · Acute Pain DFN-15 (Celecoxib Oral Solution) 62.5 mg, DFN-15 (Celecoxib… | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 120 | Aug 20, 2018 | Registry ↗ |
| Sep 23, 2020 | A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice… NCT02060903 · Head Lice Infestation Abametapir Lotion 0.74% w/w, Vehicle Lotion | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 379 | Jul 2014 | Registry ↗ |
| Aug 17, 2020 | A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to… NCT03341910 · Acne Vulgaris DFD-03 Lotion, 0.1%, Tazorac Cream, 0.1% | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 155 | May 18, 2018 | Registry ↗ |
| May 12, 2020 | Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice I… NCT02062060 · Head Lice Infestation Abametapir Lotion 0.74% w/w, Vehicle Lotion | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 325 | Jul 2014 | Registry ↗ |
| May 12, 2020 | A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of H… NCT02010333 · Head Lice Infestation Ha44 Gel 0.74% w/w | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 22 | Jul 2014 | Registry ↗ |
| Apr 29, 2020 | Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion NCT02062073 · Head Lice Abametapir Lotion 0.74% w/w, 0.1% sodium lauryl sulfate | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 238 | Mar 2014 | Registry ↗ |
| Apr 29, 2020 | An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infe… NCT01336647 · Pediculosis Group A - Low-Dose Ha44 0.37% w/w, Group B - High Dose Ha44… | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 142 | Aug 2011 | Registry ↗ |
| Apr 28, 2020 | Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation NCT01907490 · Head Lice Infestation Ha44 Gel | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 38 | Jul 2013 | Registry ↗ |
| Jan 13, 2020 | Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclon… NCT02296775 · Rheumatoid Arthritis DRL_RI, Rituxan | RDY Dr. Reddy's Laboratories Limited | Phase 1/2 | Completed | 276 | Nov 2016 | Registry ↗ |
| Dec 16, 2019 | Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer NCT02301962 · Cancer Panitumumab | RDY Dr. Reddy's Laboratories Limited | Phase 4 | Unknown | 58 | Jun 30, 2021 | Registry ↗ |
| Apr 24, 2019 | A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of… NCT03116698 · Actinic Keratosis (AK) Low dose DFD07 once daily, High dose DFD07 once daily | RDY Dr. Reddy's Laboratories Limited | Phase 2/3 | Completed | 240 | Nov 13, 2017 | Registry ↗ |
| Feb 26, 2019 | Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine NCT02571049 · Rapidly Escalating Migraine DFN-11 | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 24 | Apr 2016 | Registry ↗ |
| Jan 23, 2019 | A Study to Assess the Efficacy, Safety and Tolerability of DFD-04 NCT02828241 · Rosacea DFD-04 Ointment, Placebo Ointment | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 61 | Jan 2017 | Registry ↗ |
| Oct 18, 2018 | Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions NCT03696329 · Healthy Tetrabenazine Tablets 25 mg | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 48 | Nov 2015 | Registry ↗ |
| Oct 15, 2018 | Bioequivalence Study of Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200… NCT03706300 · Healthy Guaifenesin and Pseudoephedrine Hydrochloride Extended Rele… | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 80 | Jan 2015 | Registry ↗ |
| Oct 11, 2018 | Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions NCT03702855 · Healthy Tetrabenazine Tablets 25 mg | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 48 | Dec 2015 | Registry ↗ |
| Jul 26, 2018 | DFN-11 Injection in Episodic Migraine With or Without Aura NCT02569853 · Episodic Migraine DFN-11, Placebo | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 268 | May 30, 2017 | Registry ↗ |
| May 22, 2018 | Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches NCT02472418 · Migraine DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B) | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 63 | Dec 1, 2015 | Registry ↗ |
| Apr 3, 2018 | Pilot Study of DFN-11 Injection in Medication Overuse Headache NCT02583425 · Medication Overuse Headache DFN-11 Injection | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Terminated | 27 | Aug 2016 | Registry ↗ |
| Mar 9, 2018 | DFN-02 Open Label Safety Study in Patients With Acute Migraine NCT02279082 · Acute Migraine DFN-02 | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 167 | Sep 2015 | Registry ↗ |
| Feb 13, 2018 | Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy… NCT03282838 · Migraine DFN-15 (fasted), DFN-15 (fed) | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 24 | Aug 22, 2017 | Registry ↗ |
| Feb 13, 2018 | Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality… NCT03051685 · Healthy DFN-15 Dose 1, DFN-15 Dose 2 | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 16 | Aug 14, 2015 | Registry ↗ |
| May 19, 2017 | Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections NCT03160807 · Urinary Tract Infection Levofloxacin, Levofloxacin | RDY Dr. Reddy's Laboratories Limited | Phase 4 | Unknown | 214 | Mar 2018 | Registry ↗ |
| Mar 13, 2017 | Ketorol Gel in Gonarthrosis and Low Back Pain NCT02638831 · Gonarthrosis, Low Back Pain Ketorolac Tromethamine, Ketoprofen | RDY Dr. Reddy's Laboratories Limited | Phase 4 | Completed | 240 | Nov 2013 | Registry ↗ |
| Oct 14, 2016 | A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the T… NCT02572986 · Scabies Permethrin | RDY Dr. Reddy's Laboratories Limited | Phase 3 | Completed | 250 | Jun 2016 | Registry ↗ |
| Oct 11, 2016 | Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal S… NCT01888367 · Surgical Site Infections DFA-02 Antibiotic Gel, DFA-02 Placebo Gel | RDY Dr. Reddy's Laboratories Limited | Phase 2 | Completed | 445 | Feb 2015 | Registry ↗ |
| Oct 4, 2016 | Evaluation of the Efficacy and Safety of Nise 100 mg in the Management of Osteoarthrosis (Gonarthro… NCT02922712 · Knee Osteoarthritis NISE | RDY Dr. Reddy's Laboratories Limited | Phase 4 | Completed | 202 | Jun 2013 | Registry ↗ |
| Oct 4, 2016 | Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases NCT02922699 · GERD OMEZ 40, OMEZ 80 | RDY Dr. Reddy's Laboratories Limited | Phase 4 | Completed | 120 | Jun 2013 | Registry ↗ |
| Sep 30, 2016 | Amtolmetin Gaucil in Knee Osteoarthritis NCT02865161 · Knee Osteoarthritis NISELAT | RDY Dr. Reddy's Laboratories Limited | — | Completed | 220 | Dec 2015 | Registry ↗ |
| Sep 23, 2016 | Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection NCT02260544 · Ovarian Epithelial Cancer Recurrent Doxorubicin Hydrochloride Liposome Injection | RDY Dr. Reddy's Laboratories Limited | Phase 1 | Completed | 49 | Apr 2015 | Registry ↗ |
| Aug 16, 2016 | Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts NCT02798419 · Common Warts DFD05 Cream, Active01 Cream | RDY Dr. Reddys Laboratories, SA | Phase 2 | Completed | 50 | May 2016 | Registry ↗ |
| Mar 18, 2016 | Levofloxacin in Bacterial Rhinosinussitis NCT02712502 · Rhinosinusitis Levofloxacin, Amoxicillin-Potassium Clavulanate Combination | RDY Dr. Reddy's Laboratories Limited | — | Completed | 100 | Dec 2014 | Registry ↗ |
| Mar 17, 2016 | Non Interventional Study of Levofloxacin in Chronic Prostatitis NCT02711943 · Chronic Prostatitis Levofloxacin 500 | RDY Dr. Reddy's Laboratories Limited | — | Completed | 500 | Feb 2014 | Registry ↗ |
48 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 8:10 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances